AU2001278884A1 - Anti-hiv and anti-tumor peptides and fragments of lysozyme - Google Patents

Anti-hiv and anti-tumor peptides and fragments of lysozyme

Info

Publication number
AU2001278884A1
AU2001278884A1 AU2001278884A AU7888401A AU2001278884A1 AU 2001278884 A1 AU2001278884 A1 AU 2001278884A1 AU 2001278884 A AU2001278884 A AU 2001278884A AU 7888401 A AU7888401 A AU 7888401A AU 2001278884 A1 AU2001278884 A1 AU 2001278884A1
Authority
AU
Australia
Prior art keywords
lysozyme
fragment
hiv
fragments
tumor peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278884A
Other languages
English (en)
Inventor
Paul Huang
Philip L Huang
Sylvia Lee-Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of AU2001278884A1 publication Critical patent/AU2001278884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2001278884A 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme Abandoned AU2001278884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21670200P 2000-07-07 2000-07-07
US60216702 2000-07-07
PCT/US2001/021582 WO2002004011A1 (en) 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme

Publications (1)

Publication Number Publication Date
AU2001278884A1 true AU2001278884A1 (en) 2002-01-21

Family

ID=22808164

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278884A Abandoned AU2001278884A1 (en) 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme

Country Status (8)

Country Link
US (1) US7838275B2 (enExample)
EP (1) EP1303291B1 (enExample)
JP (1) JP2004505616A (enExample)
AT (1) ATE375800T1 (enExample)
AU (1) AU2001278884A1 (enExample)
CA (1) CA2415083A1 (enExample)
DE (1) DE60130994T2 (enExample)
WO (1) WO2002004011A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518557A4 (en) * 2002-06-28 2008-12-03 Fuso Pharmaceutical Ind ANTI-HIV AGENTS
ITMI20061950A1 (it) * 2006-10-11 2008-04-12 Therapicon Srl Effetto antimetastatico in condizioni patologiche delle cellule umane
RU2009136424A (ru) * 2007-03-02 2011-04-10 СЕНТ СИМЕОН ЭлДиЭй (US) Композиция и способ лечения папилломавируса и саркоидов лошадей
CN106029089B (zh) * 2014-02-21 2020-12-29 丘比株式会社 诺如病毒灭活剂及其制造方法
CN113861760B (zh) 2016-12-28 2023-05-05 Dic株式会社 分散体
CN110438106B (zh) * 2019-08-06 2021-03-23 北京华韵国丰新材料科技有限公司 一种人工设计的纳米溶菌酶和纳米溶菌酶的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5583211A (en) * 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
JPH06211692A (ja) * 1993-01-21 1994-08-02 Nippon Oil Co Ltd 免疫増強剤
EP0721458B1 (en) 1993-09-28 2000-05-17 Beckman Coulter, Inc. Biopolymer synthesis utilizing surface activated, organic polymers
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
GB9907366D0 (en) 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins

Also Published As

Publication number Publication date
EP1303291A4 (en) 2005-04-06
DE60130994D1 (de) 2007-11-29
DE60130994T2 (de) 2008-07-24
US20050008631A1 (en) 2005-01-13
ATE375800T1 (de) 2007-11-15
EP1303291A1 (en) 2003-04-23
EP1303291B1 (en) 2007-10-17
US7838275B2 (en) 2010-11-23
WO2002004011A1 (en) 2002-01-17
JP2004505616A (ja) 2004-02-26
CA2415083A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
CA2179286A1 (en) Broad spectrum antimicrobial compounds and methods of use
WO2002100845A8 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
MXPA04005880A (es) Cis-imidazolinas como inhibidores de la mdm2.
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2004071426A3 (en) Compounds for the treatment of viral infection
EP0301570A3 (en) Oligopeptides useful for treating aids
NZ306027A (en) Heterocyclecarbonyl amino acid hydroxyethylamin sulfonamide derivatives, preparation and use as retroviral protease inhibitors
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
DE60130994D1 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
EP0856519A3 (en) Antibacterial insect protein
JP2004505616A5 (enExample)
AU2002255562A1 (en) Virus derived antimicrobial peptides
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
PL326631A1 (en) Compounds exhibiting haemoregulatory activity
WO2003008410A8 (en) Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call
MY117535A (en) Hiv protease inhibitors
WO1999060117A3 (fr) Polypeptide prax-1
MX9706912A (es) Inhibidores de protesa retroviral de sulfonamida de hidroxietilamino de amino acido y uso de los mismos.
AU7644691A (en) Peptide compound and its preparation